Results of the TRANSLATE-POPS trial presented at TCT 2013
New study evaluates outcomes of providing access to platelet function testing in a clinical setting
Published 2013-11-01 · Original archive entry · Explore research explainers
Contact information: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Results of the TRANSLATE-POPS trial presented at TCT 2013 New study evaluates outcomes of providing access to platelet function testing in a clinical setting SAN FRANCISCO, CA – October 31, 2013 – According to a new study of heart attack patients treated with percutaneous coronary intervention (PCI), free access to platelet function testing had only a modest impact on anti-clotting drug selection and dosing. Findings of the TRANSLATE-POPS trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
While previous trials have examined platelet function testing-guided antiplatelet treatment strategies among patients undergoing PCI, little is known regarding how this testing impacts real world practice. The TRANSLATE-POPS trial evaluated whether routine availability of platelet function testing alters clinician selection and dosing of anti-clotting therapy, as well as patient outcomes after acute myocardial infarction treated with PCI. The primary end point was the rate of in-hospital therapeutic adjustments to anti-clotting therapy.
The prospective, cluster randomized trial randomly assigned sites not already routinely testing platelet function ( END
jromero@crf.org
Cardiovascular Research Foundation
Results of the TRANSLATE-POPS trial presented at TCT 2013 New study evaluates outcomes of providing access to platelet function testing in a clinical setting SAN FRANCISCO, CA – October 31, 2013 – According to a new study of heart attack patients treated with percutaneous coronary intervention (PCI), free access to platelet function testing had only a modest impact on anti-clotting drug selection and dosing. Findings of the TRANSLATE-POPS trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
While previous trials have examined platelet function testing-guided antiplatelet treatment strategies among patients undergoing PCI, little is known regarding how this testing impacts real world practice. The TRANSLATE-POPS trial evaluated whether routine availability of platelet function testing alters clinician selection and dosing of anti-clotting therapy, as well as patient outcomes after acute myocardial infarction treated with PCI. The primary end point was the rate of in-hospital therapeutic adjustments to anti-clotting therapy.
The prospective, cluster randomized trial randomly assigned sites not already routinely testing platelet function ( END